Targeting sirtuin 1/nuclear factor erythroid 2-related factor 2/tumor necrosis factor-α pathway to modulate hepatic ischemia reperfusion-induced injury

Figure 5 Immunohistochemical expression of nuclear factor erythroid-2-related factor 2 in hepatic tissues in hepatic ischemia reperfusion-induced liver injury. A: Sham group; B: Sham/aprepitant (APRE) 10 group; C: Hepatic ischemia reperfusion (HIR) group; D: HIR/APRE5 group; E: The HIR/APRE10 group; F: The HIR/APRE20 group. The HIR/APRE5 (D), HIR/APRE10 (E), and HIR/APRE20 groups (F), showed an increase in the immune staining of hepatocytes in a dose dependent manner in comparison to HIR group (C), that showed a decrease in the number of immunoreactive hepatocytes with no significant difference between either HIR/APRE10 group and HIR/APRE20 group or sham (A), and sham/APRE10 (B), groups. Results are considered significantly different when P < 0.05. ^aP < 0.05 significantly different from Sham group; ^bP < 0.05 significantly different from Sham/aprepitant (APRE) 10; ^cP < 0.05 significantly different from hepatic ischemia reperfusion (HIR) group; ^dP < 0.05 significantly different from HIR/APRE5; ^eP < 0.05 significantly different from HIR/APRE10 group. APRE5: Aprepitant 5 mg/kg; APRE10: Aprepitant 10 mg/kg; APRE20: Aprepitant 20 mg/kg; HIR: Hepatic ischemia reperfusion.